Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.60 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11152964 | 0.83 | BAZ1A (0.52) | KMT2AMEN1ALDH1A1GAALMNA | |
| SCHEMBL6037531 | 0.82 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL1649522 | 0.82 | EPHX1 (0.59) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL5759183 | 0.81 | TSHR (0.65) | NPC1RAB9ASMN1; SMN2KMT2APKM | |
| SCHEMBL10172965 | 0.81 | NPC1 (0.68) | NPC1RAB9ASMN1; SMN2SAE1UBA2 | |
| Ammonia Solution, Strong SCHEMBL11319855 | 0.80 | EPHX1 (0.57) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL29703055 | 0.80 | SMN1; SMN2 (0.77) | NPC1RAB9ASMN1; SMN2SAE1UBA2 | |
| SCHEMBL4416620 | 0.80 | SMN1; SMN2 (0.77) | NPC1RAB9ASMN1; SMN2SAE1UBA2 | |
| SCHEMBL12994616 | 0.80 | SMN1; SMN2 (0.62) | NPC1RAB9ASMN1; SMN2SAE1UBA2 | |
| Ammonia Solution, Strong SCHEMBL2058716 | 0.80 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2SAE1UBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-8013006-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | PTC THERAPEUTICS, INC. | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | EIF2AK2, INMT, IDO1 | NPC1 2173/4885RAB9A 3470/4885SMN1; SMN2 4841/4885 |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, LIPC, HCCS | NPC1 48/4885RAB9A 3241/4885SMN1; SMN2 4206/4885 |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | NPC1 297/4885RAB9A 3975/4885SMN1; SMN2 4525/4885 |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | NPC1 87/4885RAB9A 2829/4885SMN1; SMN2 3609/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | NPC1 87/4885RAB9A 2829/4885SMN1; SMN2 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.